Afynia (formerly AIMA Laboratories) is a Canadian FemTech company that has developed a home test for endometriosis, one of the leading causes of chronic and debilitating pelvic pain (CPP). In North America alone there are 8.5M incident cases of pelvic pain in women per year, representing a $2.1B market. The current path to a diagnosis of endometriosis is costly and unnecessarily long. It takes between 5-12 years and is characterized by multiple physician visits and failed treatments. AIMA’s flagship product will shorten the diagnostic path for endometriosis allowing women clarity, timely access to treatments, and reduced costs to patients and health care providers.
Southern Ontario Pharmaceutical & Health Innovation Ecosystem (SOPHIE) Program brings together Innovation Factory’s commercialization services with the Synapse Life Science Consortium’s strategic network to leverage access to Hamilton’s unique life sciences capabilities and research expertise.